A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) (clinicaltrials.gov) - Oct 16, 2026 - P2 | N=10 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Oct 2026 ➔ Oct 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2028
Trial completion date • Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|